321 518

Cited 7 times in

Can Aminoglycosides Be Used as a New Treatment for Helicobacter pylori? In vitro Activity of Recently Isolated Helicobacter pylori

DC Field Value Language
dc.contributor.author김지현-
dc.contributor.author송영구-
dc.contributor.author정다현-
dc.contributor.author정석훈-
dc.contributor.author정수진-
dc.contributor.author이경화-
dc.date.accessioned2019-10-28T02:04:41Z-
dc.date.available2019-10-28T02:04:41Z-
dc.date.issued2019-
dc.identifier.issn1598-8112-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/171473-
dc.description.abstractBACKGROUND: Smectite can serve as a drug delivery system and gentamicin-intercalated smectite hybrids are expected to supersede the standard therapy for Helicobacter pylori eradication. The aim of this study was to confirm whether the minimum inhibitory concentration (MIC) of aminoglycosides applied as smectite hybrids remained low against recently isolated H. pylori strains. MATERIALS AND METHODS: A total of 140 strains were collected for a minimum period of 3 years. Antimicrobial susceptibility tests were performed, and the MICs of eight antibiotics (amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, gentamicin, netilmicin, and tobramycin) were determined by using the Epsilometer test and following the European Committee on Antimicrobial Susceptibility Testing recommendations. RESULTS: The resistance rate of clarithromycin was high, up to 30.7%, although it is a major antimicrobial agent used in standard therapy. The MIC₅₀ and MIC₉₀ of gentamicin (0.25 mg/L and 0.75 mg/L) and netilmicin (0.19 mg/L and 0.75 mg/L) were lower than other alternative therapies for H. pylori eradication. In clarithromycin-resistant strains, the MIC₅₀ was 0.25 mg/L and the MIC₉₀ was 1 mg/L for gentamicin; for netilmicin, the values were 0.25 mg/L and 0.75 mg/L, respectively. CONCLUSION: Through the use of gentamicin and netilmicin, which have low MICs for H. pylori, aminoglycoside-intercalated smectite hybrids are expected to emerge as a new standard therapy for H. pylori eradication.-
dc.description.statementOfResponsibilityopen-
dc.languageKorean-
dc.publisher대한감염학회-
dc.relation.isPartOfInfection and Chemotherapy (감염과 화학요법)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleCan Aminoglycosides Be Used as a New Treatment for Helicobacter pylori? In vitro Activity of Recently Isolated Helicobacter pylori-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorKyoung Hwa Lee-
dc.contributor.googleauthorSoon Young Park-
dc.contributor.googleauthorSu Jin Jeong-
dc.contributor.googleauthorDa Hyun Jung-
dc.contributor.googleauthorJie-Hyun Kim-
dc.contributor.googleauthorSeok Hoon Jeong-
dc.contributor.googleauthorIl-Mo Kang-
dc.contributor.googleauthorYoung Goo Song-
dc.identifier.doi10.3947/ic.2019.51.1.10-
dc.contributor.localIdA00996-
dc.contributor.localIdA02037-
dc.contributor.localIdA03591-
dc.contributor.localIdA03619-
dc.contributor.localIdA03638-
dc.contributor.localIdA04620-
dc.relation.journalcodeJ01054-
dc.identifier.pmid30941933-
dc.subject.keywordAminoglycosides-
dc.subject.keywordClarithromycin-
dc.subject.keywordHelicobacter pylori-
dc.contributor.alternativeNameKim, Jie-Hyun-
dc.contributor.affiliatedAuthor김지현-
dc.contributor.affiliatedAuthor송영구-
dc.contributor.affiliatedAuthor정다현-
dc.contributor.affiliatedAuthor정석훈-
dc.contributor.affiliatedAuthor정수진-
dc.contributor.affiliatedAuthor이경화-
dc.citation.volume51-
dc.citation.number1-
dc.citation.startPage10-
dc.citation.endPage20-
dc.identifier.bibliographicCitationInfection and Chemotherapy (감염과 화학요법), Vol.51(1) : 10-20, 2019-
dc.identifier.rimsid62637-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.